Celldex Therapeutics (CLDX) Gross Profit (2010 - 2026)

Celldex Therapeutics' Gross Profit history runs 7 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• In Q1 2026, Gross Profit rose 2.04% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$4.4 million (down 506.34% YoY), while the FY2025 annual figure was -$4.5 million, down 415.97% from the prior year.
• Gross Profit was -$1.4 million for Q1 2026 at Celldex Therapeutics, down from -$1.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $2.1 million in Q3 2024 to a low of -$1.5 million in Q1 2025.
• Historically, Gross Profit has averaged -$498333.3 across 3 years, with a median of -$1.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Gross Profit sank 192.19% in 2025, then increased 2.04% in 2026.
• A 3-year view of Gross Profit shows it stood at -$439000.0 in 2024, then plunged by 152.16% to -$1.1 million in 2025, then plunged by 30.35% to -$1.4 million in 2026.
• The last three Gross Profit figures came in at -$1.4 million (Q1 2026), -$1.1 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.